Novel Antibiotics
33 places
Worldwide report
Every place
- 33Reports naming them
- 1Markets they lead in
- 33Regions & countries
- 2Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by Innoviva Specialty Therapeutics or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Where they show up
33 reportsOur reports that name Innoviva Specialty Therapeutics as a key player, by category and place.
- Pharmaceuticals · 33
Places 33
- Africa 1
- APAC 1
- Australia 1
- Brazil 1
- Canada 1
- China 1
- Ecuador 1
- Egypt 1
- Europe 1
France 1- Germany 1
- Global 1
Hong Kong 1
India 1
Italy 1
Japan 1
Kenya 1- Latin America 1
Malaysia 1
Mexico 1- Middle East 1
New Zealand 1- North America 1
Philippines 1
Russia 1
Saudi Arabia 1
Singapore 1
South Africa 1
Spain 1
Thailand 1- UAE 1
UK 1
US 1
Innoviva Specialty Therapeutics's markets
1Markets where they are a key player. Each opens the market's statistics for every place we cover.
Pharmaceuticals1
None of their markets match.
Recent reports naming Innoviva Specialty Therapeutics
Our newest markets with them as a key player. Each covers 2024 history, a 2025 base year and forecasts to 2034.
33 places
Companies they compete with most
Named as key players in the same markets as Innoviva Specialty Therapeutics (number of shared markets).
Merck & Co., Inc.1 shared market
Pfizer Inc.1 shared market
Shionogi1 shared market
Venatorx Pharmaceuticals1 shared market
Free public data on Innoviva Specialty Therapeutics
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Clinical trials
2 active studies led by Innoviva Specialty Therapeutics, of 2 in all
Source: ClinicalTrials.gov, Studies with Innoviva Specialty Therapeutics (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Also active in
Markets we cover where free public records show Innoviva Specialty Therapeutics: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets Innoviva Specialty Therapeutics is in.
From our blog
Stories on the topics Innoviva Specialty Therapeutics works in.
Health Data Exchange: Why EDI Matters for Payers and Providers
Behind every insurance claim is a standard electronic message. The CAQH Index says $20 billion a year could…
Read
Wound Care: Advanced Dressings for Faster Healing
Nearly 15% of US Medicare beneficiaries, 8.2 million people, had a wound or wound infection in one year…
Read
Molecular Point-of-Care Tests: Lab Accuracy, Clinic Speed
TB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade…
ReadSearch all reports for Innoviva Specialty Therapeutics All companies